NCIC CLINICAL TRIALS GROUP

GU DISEASE ORIENTED GROUP MEETING AGENDA

EATON CHELSEA HOTEL, TORONTO, ON
ROOM: STEVENSON
SATURDAY MAY 2nd, 2015, 7:00 AM – 8:00 AM

CO-CHAIRS: S. NORTH, W. KASSOUF & A. SO
SENIOR INVESTIGATOR: WENDY PARULEKAR
STUDY COORDINATOR: ALEXANDER MONTENEGRO

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies (advanced and superficial bladder) in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
- To update, review, and discuss recent results of clinical studies conducted by the NCIC Clinical Trials Group and/or by national/international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

7:00 am  Welcome

Ongoing Study Updates

7:05 am  BLC.1/SWOG S1011 Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy For Muscle Invasive Urothelial Cancer
W. Kassouf

BL.12 A Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel in Second Line Metastatic Urothelial Carcinoma
K. Sridhar

Updates on previous discussed proposals

7: 25 am  NRG-GU001 Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer
E. Winquist on behalf of L. Eapen

New studies/concept/proposals developments

7: 35 am  Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients with Bladder Cancer. SWOG S1314
S. North/W. Kassouf

Phase II Randomized Trial Assessing PD-L1 Inhibitors in BCG Refractory NMIBC
A. So

Phase III Study of Adjuvant Pembrolizumab vs. Placebo in Patients with Muscle-Invasive Bladder Cancer
K. Sridhar

8:00 am  Meeting Adjourned